BioSpace News Archive

Applied Genetic Technologies Corporation, a biotechnology company conducting human clinical trials of adeno-associated virus -based gene therapies for the treatment of rare retinal diseases, announced that it will host a virtual R&D Day from 10:00 am to 1:00 pm ET on Thursday, July 22, 2021.

LogicBio Therapeutics, Inc. today announced that Frederic Chereau , chief executive officer of LogicBio, will participate in a virtual panel discussion entitled “Delivery and Durability of Genetic Medicines” at the William Blair Biotech Focus Conference 2021 on Thursday, July 15, 2021 at 10:00 a.m. ET.

Can-Fite BioPharma Ltd today announced it has completed preparatory work ahead of the anticipated initiation of patient enrollment for its pivotal Phase III registration trial of Namodenoson in the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer.

Findings Published in Human Vaccines & Immunotherapeutics Show SAB-185 Neutralizes Virus Strains Containing Substitutions Present in Variants of Concern

The company will analyze data based on patients enrolled to date in COVID-19 Phase II studies in U.S., Europe and Israel Topline results are expected during the fourth quarter of 2021

GenapSys, Inc. today announced the addition of Dana Moss to the Company’s executive team, and further expanded the Company’s leadership team with the addition of Aric Ledford , and Richard Lyon .

BridgeBio Pharma, Inc. today announced three new academic collaborations with MUSC Foundation for Research Development, Stanford University and the University of Pittsburgh (Pitt) to translate cutting-edge discoveries into potential therapies for patients with genetic diseases and genetically driven cancers.

Novocure (NASDAQ: NVCR) announced today that it will report financial results for the second quarter 2021 on Thursday, July 29, 2021, before the U.S. financial markets open.

Selecta Biosciences, Inc. today announced that Selecta’s Chief Executive Officer, Carsten Brunn, Ph.D., will participate in one-on-one investor meetings and Chief Science Officer, Takashi Kei Kishimoto, Ph.D., will participate in a panel discussion at the William Blair Biotech Focus Conference 2021.

aTyr Pharma, Inc. today announced that the last patient has completed their last visit in the company’s Phase 1b/2a clinical trial of its lead therapeutic candidate, ATYR1923, in patients with pulmonary sarcoidosis.